Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

María Reig

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Journal of Hepatology|February 9, 2012
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial designMarta Burrel, María Reig, Alejandro Forner, et al.
Cancer|January 1, 2009
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?Alejandro Forner, Carmen Ayuso, María Varela, et al.
Insights Into Imaging|November 22, 2024
Utilizing a domain-specific large language model for LI-RADS v2018 categorization of free-text MRI reports: a feasibility studyMario Matute-González, Anna Darnell, Marc Comas-Cufí, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety studyJordi Bruix, Won-Young Tak, Antonio Gasbarrini, et al.
Hepatology (Baltimore, Md.)|January 12, 2023
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysisIsmael El Hajra, Marco Sanduzzi-Zamparelli, Víctor Sapena, et al.
Journal of Hepatology|September 1, 2014
Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cmAlejandro Forner, Ramón Vilana, Luis Bianchi, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2019
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenibÁlvaro Díaz-González, Marco Sanduzzi-Zamparelli, Víctor Sapena, et al.
European Radiology|January 7, 2021
Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patientsAnna Darnell, Jordi Rimola, Ernest Belmonte, et al.
Cancers|February 7, 2020
Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma ModelsBlanca Cucarull, Anna Tutusaus, Miguel Subías, et al.
Medicina Clinica|December 29, 2009
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]María Varela, María Reig, Manuel de la Mata, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Journal of Hepatology|February 9, 2012
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial designMarta Burrel, María Reig, Alejandro Forner, et al.
Cancer|January 1, 2009
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?Alejandro Forner, Carmen Ayuso, María Varela, et al.
Insights Into Imaging|November 22, 2024
Utilizing a domain-specific large language model for LI-RADS v2018 categorization of free-text MRI reports: a feasibility studyMario Matute-González, Anna Darnell, Marc Comas-Cufí, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety studyJordi Bruix, Won-Young Tak, Antonio Gasbarrini, et al.
Hepatology (Baltimore, Md.)|January 12, 2023
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysisIsmael El Hajra, Marco Sanduzzi-Zamparelli, Víctor Sapena, et al.
Journal of Hepatology|September 1, 2014
Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cmAlejandro Forner, Ramón Vilana, Luis Bianchi, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2019
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenibÁlvaro Díaz-González, Marco Sanduzzi-Zamparelli, Víctor Sapena, et al.
European Radiology|January 7, 2021
Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patientsAnna Darnell, Jordi Rimola, Ernest Belmonte, et al.
Cancers|February 7, 2020
Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma ModelsBlanca Cucarull, Anna Tutusaus, Miguel Subías, et al.
Medicina Clinica|December 29, 2009
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]María Varela, María Reig, Manuel de la Mata, et al.
Pageof 7